Nf1 gene inactivation in acute myeloid leukemia cells confers cytarabine resistance through MAPK and mTOR pathways

[1]  Juvenile Myelomonocytic Leukemia , 2020, Definitions.

[2]  P. Emanuel.  Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia , 2008, Leukemia.

[3]  C. Johannessen,et al.  The NF1 tumor suppressor critically regulates TSC2 and mTOR. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  C. Galmarini,et al.  Problems Related to Resistance to Cytarabine in Acute Myeloid Leukemia , 2004, Leukemia & lymphoma.

[5]  S. Lowe,et al.  Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.

[6]  Steven M Kornblau,et al.  The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies. , 2003, Reviews in clinical and experimental hematology.

[7]  H. Kantarjian,et al.  The prognostic significance of bone marrow levels of neurofibromatosis‐1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome , 2003, Cancer.

[8]  D. Largaespada,et al.  Nf1 deficiency causes Ras-Dediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia , 1996, Nature Genetics.

[9]  J. Shaughnessy,et al.  Retroviral integration at the Evi-2 locus in BXH-2 myeloid leukemia cell lines disrupts Nf1 expression without changes in steady-state Ras-GTP levels , 1995, Journal of virology.

[10]  C. Johannessen,et al.  The NF 1 tumor suppressor critically regulates TSC 2 and mTOR , 2005 .